Abaxis has entered into a definitive agreement with a medical supplies sourcing and support company to deliver its 300 Piccolo Xpress chemistry analyzers.
The biotechnology company will use CLIA waived Piccolo Xpress instruments in the course of conducting a four-year drug clinical trial.
Abaxis chairman and CEO Clint Severson said an important consideration in drug clinical trials is the impact on liver and renal function in trial participants.
"The Piccolo Xpress is the ideal point-of-care instrument to monitor real time liver and renal function to insure patient safety and accurate analysis of the efficacy of the drug compound being studied," Severson added.
Abaxis sales director Matt Rapp said, "In particular, we believe that real-time liver and renal function information during the trial could improve patient safety, comfort and convenience, while reducing the time and cost associated with shipping patient samples to off-site reference laboratories."
